Also boosted by the concept of “covid-19 treatment”, Shanghai Kaikai Industry Company Limited(600272) ( Shanghai Kaikai Industry Company Limited(600272) ) and China Meheco Group Co.Ltd(600056) ( China Meheco Group Co.Ltd(600056) ) have harvested the daily limit for three consecutive trading days. On March 4, the two companies successively issued announcements to clarify relevant rumors and remind investment risks.
After the cumulative deviation of the closing price increase of more than 20% for two consecutive trading days on March 2 and 3, Shanghai Kaikai Industry Company Limited(600272) has disclosed the change announcement on March 3, proposing that it “does not have pharmaceutical R & D, production and other related businesses”. However, on March 4, the company’s share price still rose again.
In the announcement on the 4th, Shanghai Kaikai Industry Company Limited(600272) said that the cumulative increase of the company’s short-term share price was large, the cumulative deviation from the Shanghai stock index was 31.18%, and the cumulative turnover rate was 40.08%. There may be the risk of irrational speculation. The current P / E ratio of the company is 148.9, which is significantly higher than that of the same industry.
Shanghai Kaikai Industry Company Limited(600272) concerned about recent media reports that listed the company as both traditional Chinese medicine industry and covid-19 treatment industry.
However, according to the industrial classification of national economy (GB / t47542011), the guidelines for the industrial classification of listed companies (CSRC Announcement No. 2012 [31]) issued by the China Securities Regulatory Commission and the company’s main business, Shanghai Kaikai Industry Company Limited(600272) belongs to the retail industry, not the traditional Chinese medicine industry, and does not involve covid-19 treatment related businesses at the same time.
Shanghai Kaikai Industry Company Limited(600272) is mainly engaged in pharmaceutical circulation and clothing sales, in which the pharmaceutical sector is mainly the wholesale and retail of Chinese and Western patent medicines, the pharmaceutical services of traditional Chinese medicine with the Chinese time-honored brand “leiyunshang” as the brand and the sales of high-grade tonics of its own brand “shanglei” (Maple bucket, Cordyceps sinensis, bird’s nest, sea cucumber, etc.), The company does not have pharmaceutical R & D, production and other related businesses.
Shanghai Kaikai Industry Company Limited(600272) said that after self inspection, the company’s operation was normal, the businesses of its two main businesses, clothing and medicine, were carried out normally, there were no major issues affecting the abnormal fluctuation of the company’s stock trading price, and there were no major information that should be disclosed but not disclosed.
China Meheco Group Co.Ltd(600056) , which also reaped the daily limit again on March 4, has increased by 30% in the past three trading days. The company’s main business involves four major fields: natural drugs, pharmaceutical and chemical industry, medical devices and comprehensive trade. Its business form covers the whole industrial chain of pharmaceutical industry such as R & D and production, commercial circulation and international trade.
Regarding the stock price change, China Meheco Group Co.Ltd(600056) said that the company was concerned about the recent rumors about the cooperation between the company and covid-19 virus treatment drugs, a multinational pharmaceutical company. After verification by the company, relevant matters are under communication and negotiation, but there are still uncertainties about the specific terms of the agreement and whether it can be signed smoothly.
In addition, even if the cooperation is carried out smoothly, the final use and sales of relevant drugs are also affected by factors such as epidemic prevention and control, there is great uncertainty, and it is expected that the relevant business scale accounts for a small proportion of the company’s overall business volume, which has no significant impact on the company’s recent operating performance.
Previously, China Meheco Group Co.Ltd(600056) on January 29, 2022 issued the announcement of performance reduction in 2021. It is estimated that the net profit in 2021 will be 300 million yuan to 700 million yuan, a year-on-year decrease of 77% to 47% compared with the same period of the previous year; The net profit deducted from non profits was 250 million yuan to 650 million yuan, a year-on-year decrease of 79% to 45% compared with the same period of the previous year.
China Meheco Group Co.Ltd(600056) said that the performance reduction was mainly due to the sharp year-on-year decline in export epidemic prevention business due to the change of overseas epidemic situation. At the same time, the performance of pharmaceutical industry and pharmaceutical business also decreased year-on-year due to factors such as volume procurement and adjustment of medical insurance catalogue. In addition, the company plans to withdraw relevant impairment, which has a certain impact on the performance.
